Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All paxlovid studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchPaxlovidPaxlovid (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   
0 0.5 1 1.5 2+ Time to viral- -10% Improvement Relative Risk Paxlovid for COVID-19  Guo et al.  LATE TREATMENT Is late treatment with paxlovid beneficial for COVID-19? Retrospective 1,978 patients in China (March - May 2022) Slower viral clearance with paxlovid (p=0.038) c19early.org Guo et al., BMC Infectious Diseases, Oct 2023 Favors paxlovid Favors control

In-hospital adverse outcomes and risk factors among chronic kidney disease patients infected with the omicron variant of SARS-CoV-2: a single-center retrospective study

Guo et al., BMC Infectious Diseases, doi:10.1186/s12879-023-08620-2
Oct 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Retrospective 1,978 hospitalized patients in China, showing slower viral clearance with Paxlovid. Authors note improved results in the subgroup of non-severe patients with CKD.
Confounding by contraindication. Hoertel et al. find that over 50% of patients that died had a contraindication for the use of Paxlovid Hoertel. Retrospective studies that do not exclude contraindicated patients may significantly overestimate efficacy.
Black box warning. The FDA notes that "severe, life-threatening, and/or fatal adverse reactions due to drug interactions have been reported in patients treated with paxlovid" FDA.
time to viral-, 10.0% higher, relative time 1.10, p = 0.04, treatment 779, control 1,199, median time of positive-to-negative conversion.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Guo et al., 18 Oct 2023, retrospective, China, peer-reviewed, median age 73.0, 18 authors, study period 29 March, 2022 - 17 May, 2022. Contact: haoxiangzhu2015@163.com, richengmao@gmail.com, xuejun@fudan.edu.cn, jmzhang@fudan.edu.cn.
This PaperPaxlovidAll
In-hospital adverse outcomes and risk factors among chronic kidney disease patients infected with the omicron variant of SARS-CoV-2: a single-center retrospective study
Yue Guo, Yifei Guo, Huajian Ying, Weien Yu, Shiqi Chen, Yao Zhang, Shenyan Zhang, Yanxue Lin, Feng Sun, Yongmei Zhang, Jie Yu, Ke Ma, Lunxiu Qin, Feng Long, Haoxiang Zhu, Richeng Mao, Jun Xue, Jiming Zhang
BMC Infectious Diseases, doi:10.1186/s12879-023-08620-2
Introduction The SARS-CoV-2 Omicron variant has decreased virulence and pathogenicity, yet the number of Omicron infections worldwide is unprecedentedly high, with rather high mortality and severe disease rate. Chronic kidney disease (CKD) patients are particularly vulnerable to the SARS-CoV-2 Omicron variant and have unique clinical outcomes. Methods We retrospectively collected data from 2140 hospitalized patients with SARS-CoV-2 Omicron variant infection from March 29, 2022, to May 17, 2022. Demographic characteristics, ancillary examination results, and clinical treatments were described. Occurrence of critical COVID-19 or death and time of positive-to-negative conversion was defined as primary outcomes. The presence of COVID-19 pneumonia and the usage of respiratory or circulatory support was defined as secondary outcomes. Univariate or multivariate logistic regression analyses were performed to identify risk factors for primary outcomes. Results 15.74% of CKD patients infected with the SARS-CoV-2 Omicron variant ended up with critical COVID-19 or death. Pre-existing CKD was a risk factor for critical COVID-19 or death and prolonged time of positive-to-negative conversion of SARS-CoV-2. Nirmatrelvir-ritonavir facilitated viral clearance among COVID-19 patients with non-severe CKD.
Abbreviations Supplementary Information The online version contains supplementary material available at https://doi. org/10.1186/s12879-023-08620-2. Supplementary Material 1 Authors' contributions Declarations Ethics approval and consent to participate Ethical approval was obtained from the Ethics Review Board of the Huashan Hospital, Fudan University (ethics approval registration number: KY2022-582). Informed consent forms were signed by each patient.All methods were carried out in accordance with relevant guidelines and regulations. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
Amani, Amani, Efficacy and safety of nirmatrelvir/ritonavir (paxlovid) for COVID-19: a rapid review and meta-analysis, J Med Virol
Ao, Li, Wei, Wang, Tian et al., Clinical and virological characteristics of SARS-CoV-2 Omicron BA.2.2 variant outbreaks during April to May, 2022, Shanghai, China, J Infect
Broseta, Rodriguez-Espinosa, Cuadrado, Guillen-Olmos, Hermida et al., SARS-CoV-2 infection in a spanish cohort of CKD-5D patients: prevalence, clinical presentation, outcomes, and De-Isolation results, Blood Purif
Buetti, Trimboli, Mazzuchelli, Lo Priore, Balmelli et al., Diabetes mellitus is a risk factor for prolonged SARS-CoV-2 viral shedding in lower respiratory tract samples of critically ill patients, Endocrine
Cai, Yan, Liu, Li, Ding et al., Paxlovid for hospitalized COVID-19 patients with chronic kidney disease, Antiviral Res
Cai, Yan, Wang, Mou, Efficacy of Paxlovid in patients with acute kidney injury who developed COVID-19, J Infect
Caillard, Laugel, Benotmane, Kremer, Molecular evolution of the SARS-CoV-2 omicron BA.2 variant in kidney transplant recipients with prolonged viral shedding, J Infect
Chen, Wang, Ai, Shen, Lin et al., Identification of CKD, bedridden history and cancer as higher-risk comorbidities and their impact on prognosis of hospitalized Omicron patients: a multicentre cohort study, Emerg Microbes Infect
Chung, Palmer, Natale, Krishnan, Cooper et al., Incidence and outcomes of COVID-19 in people with CKD: a systematic review and Meta-analysis, Am J Kidney Dis
Danthu, Hantz, Dahlem, Duval, Ba et al., Humoral response after SARS-CoV-2 mRNA vaccination in a cohort of Hemodialysis patients and kidney transplant recipients, J Am Soc Nephrol
Devresse, Sebastien, Greef, Lemaitre, Boland et al., Safety, Efficacy, and relapse of nirmatrelvir-ritonavir in kidney transplant recipients infected with SARS-CoV-2, Kidney Int Rep
Flythe, Assimon, Tugman, Chang, Gupta et al., Characteristics and outcomes of individuals with pre-existing kidney disease and COVID-19 admitted to Intensive Care Units in the United States, Am J Kidney Dis
Gao, Zhu, Jin, Tong, Xiao et al., Proinflammatory cytokines are associated with prolonged viral RNA shedding in COVID-19 patients, Clin Immunol
Hao, Lian, Lu, Jia, Hu et al., Decreased B cells on Admission Associated with prolonged viral RNA shedding from the respiratory tract in Coronavirus Disease 2019: a case-control study, J Infect Dis
Kaso, Hareru, Kaso, Agero, Factors Associated with Poor Treatment Outcome among Hospitalized COVID-19 Patients in South Central, Ethiopia, Biomed Res Int
Kim, Lee, Choi, Um, Lee et al., Clinical characteristics of 40 patients infected with the SARS-CoV-2 Omicron variant in Korea, J Korean Med Sci
Lee, Tay, Sutjipto, Fong, Ong et al., Associations of viral ribonucleic acid (RNA) shedding patterns with clinical illness and immune responses in severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, Clin Transl Immunology
Li, Liao, Zhou, Wang, Yang et al., Association between glucocorticoids treatment and viral clearance delay in patients with COVID-19: a systematic review and meta-analysis, BMC Infect Dis
Mahalingasivam, Su, Iwagami, Davids, Wetmore et al., COVID-19 and kidney disease: insights from epidemiology to inform clinical practice, Nat Rev Nephrol
Meiring, Tempia, Bhiman, Buys, Kleynhans et al., Prolonged shedding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at high viral loads among hospitalized immunocompromised persons living with Human Immunodeficiency Virus (HIV), South Africa, Clin Infect Dis
Nakajima, Ogai, Furukawa, Arai, Anan et al., Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient, J Infect Chemother
Pei, Chen, Zheng, Gong, Liu et al., Comorbidities prolonged viral shedding of patients infected with SARS-CoV-2 omicron variant in Shanghai: a multi-center, retrospective, observational study, J Infect Public Health
Planas, Saunders, Maes, Guivel-Benhassine, Planchais et al., Considerable escape of SARS-CoV-2 Omicron to antibody neutralization, Nature
Shaikh, Zeldis, Campbell, Chan, Prolonged SARS-CoV-2 viral RNA shedding and IgG antibody response to SARS-CoV-2 in patients on Hemodialysis, Clin J Am Soc Nephrol
Sun, Lin, Wang, Gao, Ye, Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection, Lancet Infect Dis
Uraki, Kiso, Iida, Imai, Takashita et al., Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2, Nature
Wang, Zhao, Liu, Chen, Feng, Early administration of Paxlovid reduces the viral elimination time in patients infected with SARS-CoV-2 omicron variants, J Med Virol
Weng, Xie, Han, Yuan, Li et al., Safety and Efficacy of Paxlovid against Omicron Variants of Coronavirus Disease 2019 in Elderly Patients, Infect Dis Ther
Williamson, Walker, Bhaskaran, Bacon, Bates et al., Factors associated with COVID-19-related death using OpenSAFELY, Nature
Wolter, Jassat, Gottberg, Cohen, Da-Ga, Clinical severity of omicron lineage BA.2 infection compared with BA.1 infection in South Africa, Lancet
Wolter, Jassat, Walaza, Welch, Moultrie et al., Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study, Lancet
Yu, Guo, Zhang, Kong, Shen et al., Proportion of asymptomatic infection and nonsevere disease caused by SARS-CoV-2 Omicron variant: a systematic review and analysis, J Med Virol
Zhong, Jiang, Yang, Feng, Duan et al., The efficacy of paxlovid in elderly patients infected with SARS-CoV-2 omicron variants: results of a non-randomized clinical trial, Front Med
Zhou, Huang, Sun, Tian, Xue et al., Chronological changes of viral shedding in adult inpatients with Omicron infection in Shanghai, China, Front Immunol
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit